The global gene editing market is estimated to grow at a significant CAGR of over 14% during the forecast period. The market growth is attributed to the increasing prevalence of genetic disorders, increasing demand for precision medicines, and a significant rise in the R&D expenditure by the industry players. Some of the players operating in the global gene editing industry include GenScript Technologies Corp., Merck KGaA, Integrated DNA Technologies Inc. (Danaher Corp.), Horizon Discovery Group PLC, Sangamo Therapeutics Inc., Thermo Fisher Scientific Inc., and CRISPR Therapeutics AG, among others.

Request a Free Sample of our Gene Editing Market: https://www.omrglobal.com/request-sample/gene-editing-market

The players are majorly focusing on CRISPR technology in the global gene editing market. With the increasing importance of CRISPR technology, players such as Thermo Fisher Scientific Inc. has established presence in diversified life sciences markets, which has vanished the risk and dependency on any business segment. The company has a robust product line which enables it to further strengthen its position in the global gene editing market. in June 2017, the company launched a program of four-day lecture-based and hands-on CRISPR and TALEN genome-editing workshops at its global training facilities.

A full Report of Gene Editing Market is Available at: https://www.omrglobal.com/industry-reports/gene-editing-market

CRISPR Therapeutics AG is another major player operating in the global gene editing market. The company uses the CRISPR gene-editing method. The lead candidate of the company CTX001, is currently in phase 1 clinical studies, and it targets blood diseases such as beta thalassemia and sickle cell disease (SCD). In June 2019, Vertex Pharmaceuticals Inc. expanded its collaboration with CRISPR Therapeutics and completed the acquisition of Exonics Therapeutics to enhance its gene editing capabilities for the development of novel therapies for Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1).
Through the expanded collaboration with CRISPR and the acquisition of Exonics, the company is aimed at bringing together the intellectual property, technologies, and scientific expertise needed for establishing a leading gene editing platform for DMD and DM1.
Global Gene Editing Market Segmentation

By Technology

• Clustered regularly interspaced short palindromic repeats (CRISPR)
• Transcription activator-like effector nuclease (TALEN)
• Zinc Finger Nuclease (ZFN)
• Others
By Application

• Cell Line Editing
• Animal Genome Editing
• Plant Genome Editing
• Others
Global Gene Editing Market – Segmentation by Region

North America

• United States
• Canada
Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe
Asia-Pacific
• China
• Japan
• India
• Rest of Asia-Pacific
Rest of the World

Company Profiles

• Allele Biotech and Pharmaceuticals, Inc.
• Arcadia Biosciences
• Beam Therapeutics Inc.
• Bio Palette Co., Ltd.
• Bio-Rad Laboratories, Inc.
• Caribou Bioscience Inc.
• Cibus Ltd.
• CRISPR Therapeutics AG
• Editas Medicine
• Evogene Ltd.
• GeneCopoeia Inc.
• GenScript Biotech Corp.
• Horizon Discovery Group PLC
• Integrated DNA Technologies Inc. (Danaher Corp.)
• Lonza Group AG
• MerckKGaA
• New England Biolabs Inc.
• Origene Technologies, Inc.
• SangamoTherapeutics,Inc.
• Synthetic Genomics Inc.
• Takara Bio, Inc.
• Thermo Fisher Scientific, Inc.
• Transposagen Biopharmaceuticals Inc.
• Tropicbioscience UK Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/gene-editing-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 7803040404